Log In

Forgot Password?
Create New Account

Loading... please wait

2021 Annual Meeting | Epilepsy/Clinical Neurophysiology (EEG) Posters

This program spans the entire conference
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Scientific Poster Session
Epilepsy/Clinical Neurophysiology (EEG)
0.00 credit
COVID-19

Program Materials Program Evaluations

Event Timeline
07:00 AM - 05:00 PM EDT Abstract 001 - PROVE Study 506: Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients Based on Study Site Participation in Previous Clinical Trials
Robert T. Wechsler, MD, PhD, FAAN
07:00 AM - 05:00 PM EDT Abstract 002 - Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) in an Open-Label Extension (OLE) Trial (GWPCARE6)
James W. Wheless, MD, FAAP, FAAN
07:00 AM - 05:00 PM EDT Abstract 003 - Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
Cecil D. Hahn, MD
07:00 AM - 05:00 PM EDT Abstract 004 - Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Tuberous Sclerosis Complex (TSC) and a History of Infantile Spasms (IS): Post Hoc Analysis of Phase 3 Trial GWPCARE6
James W. Wheless, MD, FAAP, FAAN
07:00 AM - 05:00 PM EDT Abstract 005 - Dose Adjustments to Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for Treatment of Uncontrolled Focal Seizures
William E. Rosenfeld, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 006 - Consistent and Durable Long-Term Efficacy from Two Open-Label Studies of Cenobamate
William E. Rosenfeld, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 007 - Efficacy and Safety of Low- and High-Dose Perampanel as First Adjunctive Therapy in Patients With Partial-Onset Seizures (POS) With or Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of the FAME Study
Dae W. Seo, MD
07:00 AM - 05:00 PM EDT Abstract 008 - Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients With Partial-Onset Seizures (POS), With/Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM)
Ryan Edbert Husni
07:00 AM - 05:00 PM EDT Abstract 009 - Long-Term (1-Year) Evaluation of Adjunctive Perampanel on Mental Health in Pediatric Patients (Aged 4-<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311
Rohit Shankar
07:00 AM - 05:00 PM EDT Abstract 010 - Long-Term (1-Year) Seizure Freedom with Adjunctive Perampanel in Pediatric Patients (Aged 4–<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Study 311
Robert Flamini, MD
07:00 AM - 05:00 PM EDT Abstract 011 - Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for Treatment of Uncontrolled Focal Seizures: Effects of Dose Reductions to Concomitant Lamotrigine and Carbamazepine
Louis Ferrari
07:00 AM - 05:00 PM EDT Abstract 012 - Efficacy of Adjunctive Eslicarbazepine Acetate in Patients with Focal Seizures, According to Baseline Seizure Frequency: A Post-Hoc Analysis of Data from a Phase IV Clinical Trial
Sami M. Aboumatar, MD
07:00 AM - 05:00 PM EDT Abstract 013 - Efficacy of Cenobamate by Concomitant Antiseizure Medications in Patients With Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study
Pavel Klein, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 014 - Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as an Adjunctive Therapy in Patients with 15q Duplication Syndrome (Dup15q) or Cyclin-Dependent Kinase-Like 5 Deficiency Disorder (CDD) in a Signal-Finding Phase 2 Study (ARCADE)
Scott T. Demarest, MD
07:00 AM - 05:00 PM EDT Abstract 015 - Post-hoc Analysis of the Effects of Dose Reductions of Concomitant Clobazam in a Phase 3, Open-Label Study of Cenobamate for the Treatment of Uncontrolled Focal Seizures
Bassel W. Abou-Khalil, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 016 - Efficacy and Safety of Cannabidiol (CBD) in Patients with Treatment-Resistant Epilepsies (TREs) in the Expanded Access Program (EAP): Additional Efficacy Data for Convulsive and Nonconvulsive Seizure Types
Paul Lyons, MD
07:00 AM - 05:00 PM EDT Abstract 017 - MOMENTUM (Study 304; NCT04572243): A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of Adjunctive Lorcaserin in Patients with Dravet Syndrome (DS)
Orrin Devinsky, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 018 - ELEVATE Study 410 Initial Results: Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients Aged =4 Years with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS)
Vineet Punia, MD
07:00 AM - 05:00 PM EDT Abstract 019 - Efficacy and Safety of Adjunctive Perampanel for Myoclonic and Absence Seizures: Post Hoc Pooled Analysis of Adult, Adolescent, and Pediatric Patients in Studies 332, 311, and 232
Christian Brandt, MD
07:00 AM - 05:00 PM EDT Abstract 020 - Perampanel Monotherapy for the Treatment of Epilepsy: Evidence From a Clinical Trial (Study 342) and Real-World Use (Studies 504 and 506)
Antonio Gil-Nagel, MD
07:00 AM - 05:00 PM EDT Abstract 021 - Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study
Wendyl J. D'Souza, MD, MBChB
07:00 AM - 05:00 PM EDT Abstract 022 - Seizure Reduction With Adjunctive Cenobamate During Titration in the Phase 3 C021 Study
Victor Biton, MD
07:00 AM - 05:00 PM EDT Abstract 023 - Adjunctive Cenobamate Dose in Seizure-Free Patients by Baseline Seizures in the Phase 3 C021 Study
Sami M. Aboumatar, MD
07:00 AM - 05:00 PM EDT Abstract 024 - Long-Term Efficacy of Cenobamate by Concomitant Antiseizure Medication: Post-hoc Analysis of the C017 Open-label Extension Study
Louis Ferrari
07:00 AM - 05:00 PM EDT Abstract 025 - Long-term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP)
Leon A. Weinstock, MD
07:00 AM - 05:00 PM EDT Abstract 026 - Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal-onset seizures: Post-hoc analysis from a phase III, randomized, double-blind study and a 2-year open-label extension ESL study
Eugen Trinka
07:00 AM - 05:00 PM EDT Abstract 027 - Diagnostic Yield of Electroencephalography When Seizure is Suspected in Acute Ischemic Stroke
Prathana Hareesh, MBBS
07:00 AM - 05:00 PM EDT Abstract 028 - LRDA and LPDs EEG patterns association with seizures in critically ill patients: a systematic review
Faisal A. Ibrahim, MD
07:00 AM - 05:00 PM EDT Abstract 029 - Events Recording in Patients who Underwent Ambulatory EEG and Inpatient EEG Monitoring
Yara Mikhaeil-Demo, MD
07:00 AM - 05:00 PM EDT Abstract 030 - Continuous EEG Monitoring in Aneurysmal Subarachnoid Hemorrhage: Clinical Outcomes and Costs
Jafar Hashem, MD
07:00 AM - 05:00 PM EDT Abstract 031 - EEG Reactivity and Evoked Response Testing Predict Positive Outcomes Following Cardiac Arrest
Bryan D. Clements II, DO
07:00 AM - 05:00 PM EDT Abstract 032 - Use of Continuous Electroencephalogram (cEEG) in Critically Ill Patients
Ahyuda Oh, PhD
07:00 AM - 05:00 PM EDT Abstract 033 - How Much Time is Enough? Establishing an Optimal Duration of Recording for Ambulatory Video EEG
Hans Klein, PhD
07:00 AM - 05:00 PM EDT Abstract 034 - Clinical characteristics Associated With Delayed Seizure Detection Among Critically Ill Patients undergoing Continuous EEG(cEEG) Monitoring
Ifrah Zawar, MD
07:00 AM - 05:00 PM EDT Abstract 035 - Quantitative EEG Markers of Hypoglycemia
Sergiu I. Abramovici, MD
07:00 AM - 05:00 PM EDT Abstract 036 - Extreme Delta Brush: The Key to Anti-NMDA Receptor Encephalitis
Courtney Filliben
07:00 AM - 05:00 PM EDT Abstract 037 - Unique EEG findings in Hashimoto Encephalitis – Migrating lateralized periodic discharges – case report
Sushma R. Yerram, MD
07:00 AM - 05:00 PM EDT Abstract 038 - Improving Ictal Testing in the Epilepsy Monitoring Unit via Assessment Standardization (Long-term Follow Up)
Brian J. Hanrahan, MD
07:00 AM - 05:00 PM EDT Abstract 039 - Concordance Between Patient-Reported And Physician-Reported Seizure Semiology
Andrew Lin, MD
07:00 AM - 05:00 PM EDT Abstract 040 - Characterizing the Driving Dilemma among Patients with Nonepileptic Events: A Single-Center Prospective Cohort Study
Sara Dawit, MD
07:00 AM - 05:00 PM EDT Abstract 041 - Psychogenic non-epileptic seizures with comorbid epilepsy: insights from patient and caregiver characteristics
Aida Risman, MD
07:00 AM - 05:00 PM EDT Abstract 042 - A Descriptive Study of Eye Movements in Versive Seizures
Neel Fotedar, MD
07:00 AM - 05:00 PM EDT Abstract 043 - Dissociative seizures across the adult lifespan: female sex, delay to diagnosis and disability
Wesley Kerr, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 044 - The Role of Semantic Saliency in Reading Epilepsy: A Case Report
Wentao Li, MD
07:00 AM - 05:00 PM EDT Abstract 045 - Two Cases of Scalp EEG Negative, Stereotactic EEG Proven Insular Epilepsy with Interesting Semiologies
Denise Li, MD
07:00 AM - 05:00 PM EDT Abstract 046 - Excessive Yawning as an Ictal Manifestation of Post-stroke Seizures
Anna McDonnell
07:00 AM - 05:00 PM EDT Abstract 047 - Postictal Psychosis and Postictal Delirium: A Report of Five Cases
07:00 AM - 05:00 PM EDT Abstract 048 - Quantitative EEG during alteration of consciousness in psychogenic non-epileptic seizures
Katherine Werbaneth, MD
07:00 AM - 05:00 PM EDT Abstract 049 - Depression and Anxiety Precede the Onset of Spells in Patients with Psychogenic Nonepileptic Seizures
Omar Nofal, MD
07:00 AM - 05:00 PM EDT Abstract 050 - Characterization of Electroencephalographic Abnormalities and Their Radiographic Correlates Associated with COVID-19
Ahmad A. Ballout, MD
07:00 AM - 05:00 PM EDT Abstract 051 - Changes in Health-Seeking Behavior Among Adult and Pediatric Patients with Seizures during the COVID-19 Pandemic
William C. Leung, MBBS, MRCP, FHKAM
07:00 AM - 05:00 PM EDT Abstract 052 - Electroencephalographic findings in hospitalized patients with SARS-COV-2 (COVID-19) encephalopathy
Niyatee Samudra, MD
07:00 AM - 05:00 PM EDT Abstract 053 - Electroencephalographic findings in COVID-19 patients: A systematic review
Katrina Roberto, MD
07:00 AM - 05:00 PM EDT Abstract 054 - Status epilepticus and other epileptiform EEG findings in patients with COVID-19
Katherine Werbaneth, MD
07:00 AM - 05:00 PM EDT Abstract 055 - EEG Findings in COVID-19 Positive Patients: A Case Series
Uma Menon, MD, MBA, FAAN
07:00 AM - 05:00 PM EDT Abstract 056 - Ceribell EEG Shortens Seizure Diagnosis and Workforce Time and Is Useful for COVID Isolation
Marian P. LaMonte, MD, MSN, FAAN
07:00 AM - 05:00 PM EDT Abstract 057 - The Efficacy, Safety and Outcomes of Responsive neurostimulation (RNS) therapy in Older Adults
Ifrah Zawar, MD
07:00 AM - 05:00 PM EDT Abstract 058 - Antiepileptic Drugs Use after Deep Brain Stimulation Therapy
Haley Phillips, MD
07:00 AM - 05:00 PM EDT Abstract 059 - Vagus Nerve Stimulation AutoStim Feature, A Three-Year Study
Prashant K. Rai, MD
07:00 AM - 05:00 PM EDT Abstract 060 - A Case of Super-Refractory Epilepsia Partialis Continua Successfully Treated with Repetitive Transcranial Magnetic Stimulation
Busranur Agac, MD
07:00 AM - 05:00 PM EDT Abstract 061 - VNS Used In The Elderly Population
Ana Suller Marti, MD
07:00 AM - 05:00 PM EDT Abstract 062 - Brain Responsive Stimulation for Treatment of Refractory Frontal Lobe Epilepsy
Carolyn Tsai, MD
07:00 AM - 05:00 PM EDT Abstract 063 - Crescendo in EKG Heterogeneity Is Superior to Heart Rate Elevation as a Warning Sign of Impending Generalized Tonic-Clonic Seizures
Trudy Pang, MD
07:00 AM - 05:00 PM EDT Abstract 064 - Analysis of Brief Potentially Ictal Rhythmic Discharges (BIRDs) and seizures in Epilepsy Patients with Responsive Neurostimulation undergoing Scalp Electroencephalography
Hernan Nicolas Lemus Esquivel, MD
07:00 AM - 05:00 PM EDT Abstract 065 - Integrated Digital System for Long-term Behavioral Tracking and Adaptive Electrical Brain Stimulation: Canines and Humans with Epilepsy
Vaclav Kremen
07:00 AM - 05:00 PM EDT Abstract 066 - Preclinical Development of Human Inhibitory Interneuron Cell Therapy (NTX-001) for Chronic Focal Epilepsy
Mansi B. Parekh, PhD
07:00 AM - 05:00 PM EDT Abstract 067 - Relationship Between Genetic Variants and Disease Characteristics in Patients with SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE) or SCN8A-Related Epilepsy
Dietrich Haubenberger, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 069 - Evaluating the Epidemiological Burden of KCNQ2 Epilepsy
Celene Grayson, PhD
07:00 AM - 05:00 PM EDT Abstract 070 - Electroclinical Features in MECP2 Duplication Syndrome: Pediatric case series
Jocelyn B. Lorenzo, MD
07:00 AM - 05:00 PM EDT Abstract 071 - Utility of Genetic Testing in Epilepsy Surgery Decision Making
Irina Podkorytova
07:00 AM - 05:00 PM EDT Abstract 072 - Alternating Seizure Focus In Mitochondrial Disease
Yazan Nofal, MD
07:00 AM - 05:00 PM EDT Abstract 073 - Genetic Variation Associated with Post-operative Seizure Freedom in Temporal Lobe Epilepsy
Shreya Louis, MD
07:00 AM - 05:00 PM EDT Abstract 074 - Caregivers’ Perspectives on the Long-term Seizure- and Non-seizure-related Benefits of Fenfluramine on Patients with Dravet Syndrome and their Families
Dagmar Amtmann
07:00 AM - 05:00 PM EDT Abstract 075 - Long-Term Anti-Seizure Medication Continuation after Acute Strokes
Pradeep Chandan, DO
07:00 AM - 05:00 PM EDT Abstract 076 - Differences in rates of elective video-EEG monitoring admission by race/ethnicity and insurance status in New Jersey
Brad K. Kamitaki, MD
07:00 AM - 05:00 PM EDT Abstract 077 - Evaluation of Epilepsy Patients to Ascertain Risk Factors for 30-day Hospital Readmission
Aakriti Kothiwal
07:00 AM - 05:00 PM EDT Abstract 078 - Women with Epilepsy and Postpartum Toxicity: A Retrospective Analysis
Leslie Siegel, PharmD
07:00 AM - 05:00 PM EDT Abstract 079 - Postraumatic epilepsy in patients with traumatic brain injury and computed tomography lesions
07:00 AM - 05:00 PM EDT Abstract 080 - Generalized epilepsy in the elderly undergoing epilepsy monitoring unit evaluation.
Majed Alzahrany, MBBS
07:00 AM - 05:00 PM EDT Abstract 081 - The effect of weight reduction surgery on antiseizure drug levels and seizure frequency.
James D. Triplett, MBBS
07:00 AM - 05:00 PM EDT Abstract 082 - Evaluation of medication adherence in an inter-professional epilepsy clinic
Caroline Kim, Pharmacist
07:00 AM - 05:00 PM EDT Abstract 083 - Pre-Surgical Evaluation and Management of Drug-Resistant Post-Stroke Epilepsy
Miguel Arevalo Astrada
07:00 AM - 05:00 PM EDT Abstract 084 - Treatment gaps and challenges in epilepsy care in the Philippines
07:00 AM - 05:00 PM EDT Abstract 085 - Post-traumatic Epilepsy (PTE): Clinical, Radiographic and Electroencephalographic Features and Outcome
Hira Pervez, MD, MBBS
07:00 AM - 05:00 PM EDT Abstract 086 - Role of Anti-Seizure Drugs in the Treatment of Post-Stroke Seizures; Results Analysis from Retrospective Epilepsy Database
Sidra Saleem, MD
07:00 AM - 05:00 PM EDT Abstract 087 - How #Epilepsy is Viewed on Social Media
Steven Gangloff, MD
07:00 AM - 05:00 PM EDT Abstract 088 - Coping And Resilience In Epilepsy : A Descriptive Study
07:00 AM - 05:00 PM EDT Abstract 089 - Reducing Emergency Room Visits for Patients with Epilepsy: A Quality Improvement Project
Ramsha A. Bhutta, MD
07:00 AM - 05:00 PM EDT Abstract 090 - Seizures After Liver Transplant
Franco E. Appiani, MD
07:00 AM - 05:00 PM EDT Abstract 091 - Seizures and Kidney Transplantation: description of a 10-year cohort
07:00 AM - 05:00 PM EDT Abstract 092 - Bupropion Overdose Induced Reversible Burst Suppression and Myoclonic Seizures
Monica J. Goodman
07:00 AM - 05:00 PM EDT Abstract 093 - Factors influencing on quality of life in patients with epilepsy
07:00 AM - 05:00 PM EDT Abstract 094 - Evaluation of Epilepsy Sub-Classification and Optimal Treatment Plan in Post-Stroke Epilepsy: A Single Center Experience
Lilly Fagatele
07:00 AM - 05:00 PM EDT Abstract 095 - Natural Progesterone Reduces Seizures in Women with Epilepsy with Strong Catamenial Tendency: A Pilot Study
Alise K. Carlson, MD
07:00 AM - 05:00 PM EDT Abstract 096 - Treatment of Adult Onset Rasmussen's Encephalitis with Tocilizumab
Sotiris G. Mitropanopoulos, MD
07:00 AM - 05:00 PM EDT Abstract 097 - Racial Differences in Mortality from Status Epilepticus
Ali A. Fadhil, MD
07:00 AM - 05:00 PM EDT Abstract 098 - Time to Loading Conventional Anti-seizure Medications in Patients with Status Epilepticus: A Quality Improvement Project
Arooj Kohli, MD
07:00 AM - 05:00 PM EDT Abstract 099 - Low Pyridoxine levels are associated with Status Epilepticus
Clio A. Rubinos, MD
07:00 AM - 05:00 PM EDT Abstract 100 - Posterior Reversible Encephalopathy Syndrome Presenting with Epilepsia Partialis Continua induced by Pseudo-hyperaldosteronism Secondary to Chronic Ingestion of Licorice
Faddi G. Saleh Velez, MD
07:00 AM - 05:00 PM EDT Abstract 101 - Subacute encephalopathy with seizures in alcoholics (SESA) syndrome – a subtype of non-convulsive status epilepticus (NCSE).
Aissata Diawara, MD
07:00 AM - 05:00 PM EDT Abstract 102 - Characterization of Memory Outcome Following Temporal Lobe Resection in Children with Epilepsy
Navkiranjot Kaur
07:00 AM - 05:00 PM EDT Abstract 103 - Perampanel Blocks Refractory Status Epilepticus and its Consequences.
Claude G. Wasterlain, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 104 - Patient Preference of Anterior Temporal Lobe Lobectomy versus Laser Interstitial Thermal Therapy
Aissata Diawara, MD
07:00 AM - 05:00 PM EDT Abstract 105 - Changes in fractional amplitude of low frequency fluctuations (fALFF) changes after epilepsy surgery in patients with temporal lobe epilepsy
Niyatee Samudra, MD
07:00 AM - 05:00 PM EDT Abstract 106 - Levetiracetam and Lacosamide in the treatment of Non-Convulsive Status Epilepticus
Asia Payne, MD
07:00 AM - 05:00 PM EDT Abstract 107 - Comparison of EEG and Neuroimaging Modalities in Localizing Epileptogenic Foci in Pediatric Epilepsy Surgery
Min Ye Shen, MD
07:00 AM - 05:00 PM EDT Abstract 108 - The Impact of Surgical Treatment on the Driving Status of Adults with Refractory Epilepsy
Amanda Bingaman
07:00 AM - 05:00 PM EDT Abstract 109 - Health State Utility Values in Paediatric Subjects with Partial Onset Seizures (POS) or Primary Generalized Tonic Clonic Seizures (PGTCS) receiving Adjunctive Perampanel
Andrew Trigg
07:00 AM - 05:00 PM EDT Abstract 110 - Safety and Tolerability of Intravenous Brivaracetam in Patients with Epilepsy on Concomitant Levetiracetam Treatment
Melinda S. Martin, PhD
07:00 AM - 05:00 PM EDT Abstract 111 - Perampanel Monotherapy in Epilepsy Patients with Focal and Generalized Seizures: Real-World Experience
Taoufik Alsaadi, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 112 - Anti-Seizure Drug Rescue of Voltage Gated Sodium Channel Trafficking Deficient Mutants
Jamie A. Simpson
07:00 AM - 05:00 PM EDT Abstract 113 - Investigation of the differential impact of cannabinoid compounds on seizure frequency and quality of life in patients with epilepsy
Danielle S. McDermott, MD
07:00 AM - 05:00 PM EDT Abstract 114 - Transition from Intravenous to Enteral Administration of Levetiracetam and Lacosamide in the Hospital Setting: Preliminary Data
Yong-Bum Song, PharmD
07:00 AM - 05:00 PM EDT Abstract 115 - A Paradoxical Phenomenon: Seizure Exacerbation following Administration of Anti-seizure Drugs
Maria Jaramillo, MD
07:00 AM - 05:00 PM EDT Abstract 116 - Clinical Update For Cenobamate: Patients’ Experiences of Efficacy and Side Effects
Julia Bodnya, MD
07:00 AM - 05:00 PM EDT Abstract 117 - Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice
Estevo Santamarina
07:00 AM - 05:00 PM EDT Abstract 118 - Ten years of post-marketing surveillance data of Eslicarbazepine acetate: reinforcement of the adult safety profile evidenced in clinical trials
Helena Gama
07:00 AM - 05:00 PM EDT Abstract 119 - The effect of epilepsy on sleep quality during pregnancy and postpartum
Sheela Toprani, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 120 - Bone density screening in epilepsy patients
Jose A. Montes-Rivera, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 121 - The utility of the GAD-7 anxiety, NDDI-E depression, Epworth sleepiness and QOLIE-31-P quality of life scales in patients with epilepsy in real clinical practice
Alicia Gonzalez-Martinez, MD
07:00 AM - 05:00 PM EDT Abstract 122 - The Co-occurrence of Dementia in those with Epilepsy is Associated with 30-day Readmission - A Population-based Study
Helaina Lehrer, MD
07:00 AM - 05:00 PM EDT Abstract 123 - Sleep central apnea does not correlate with peri-ictal breathing dysfunction
Yao Cheng, MBBS
07:00 AM - 05:00 PM EDT Abstract 124 - The Effects of Psychiatric Co-Morbidity on Recurrent Emergency Department (ED) Visits in Patients with Epileptic Seizures – Experience from a Single County Hospital
Anika Morgado
07:00 AM - 05:00 PM EDT Abstract 125 - Factors that Affect the Employability of Patients with Epilepsy in Hawaii: A Look at Race, Comorbidities, and Marital Status.
Rachel Gorenflo
07:00 AM - 05:00 PM EDT Abstract 126 - Subjective Memory Complaints and Memory Dysfunction in Epilepsy
Kristin Bumsch
07:00 AM - 05:00 PM EDT Abstract 127 - Evaluation of Diazepam Nasal Spray in Patients with Epilepsy Concomitantly Using Maintenance Benzodiazepines: Interim Analysis from a Phase 3, Long-term, Open-label Safety Study
Eric Segal, MD
07:00 AM - 05:00 PM EDT Abstract 128 - Treatment Satisfaction, Anxiety Level, and Confidence About Traveling With Midazolam Nasal Spray in Patients With Seizure Clusters: Phase III, Open-Label Extension Trial
Toufic Fakhoury, MD
07:00 AM - 05:00 PM EDT Abstract 129 - Time to Second Doses in Emergency Seizure Patients Treated With Valtoco® (diazepam nasal spray) Across 24 Hours: Subgroup Results From a Completed Phase 3, Open-label, Repeat Dose Safety Study
James W. Wheless, MD, FAAP, FAAN
07:00 AM - 05:00 PM EDT Abstract 130 - Examining the Patient Experience With Diazepam Nasal Spray for Seizure Clusters: Patient-reported Results From an Exit Survey of a Phase 3, Open-label, Repeat Dose Safety Study
Patricia E. Penovich, MD, FAAN
07:00 AM - 05:00 PM EDT Abstract 131 - Return to Full Baseline Functionality After Repeated Intermittent Use of Midazolam Nasal Spray in Patients With Seizure Clusters: Post-Hoc Analysis of an Open-Label Extension Trial
Kamil Detyniecki, MD
07:00 AM - 05:00 PM EDT Abstract 132 - Exploring the Impact of Need for a Second Dose of Rescue Therapy for Seizure Episodes on Healthcare Utilization
07:00 AM - 05:00 PM EDT Abstract 133 - Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study
James W. Wheless, MD, FAAP, FAAN
07:00 AM - 05:00 PM EDT Abstract 134 - Intravenous Antiseizure Medication Utilization Patterns Among Seizure Patients Treated in US Hospitals: a Database Analysis
Prashant Dongre, MD, MBBS
07:00 AM - 05:00 PM EDT Abstract 135 - Outcomes of Intravenous Use of Brivaracetam and Levetiracetam for the Treatment of Seizures in US Hospitals
Prashant Dongre, MD, MBBS
07:00 AM - 05:00 PM EDT Abstract 136 - Focused ultrasound ablation of the anterior thalamus for epilepsy
Vibhor Krishna
07:00 AM - 05:00 PM EDT Abstract 137 - Imaging findings and prognostic implications of hippocampal sclerosis subtypes.
Shreya Louis, MD
07:00 AM - 05:00 PM EDT Abstract 138 - Hippocampal Atrophy and Quantitative EEG Markers in Mild Cognitive Impairment in Temporal Lobe Epilepsy versus Extra-Temporal Lobe Epilepsy
Mohammed A. ElSherif, MD, PhD, FAAN
07:00 AM - 05:00 PM EDT Abstract 139 - Kratom-Induced Seizures Associated With Reversible Basal Ganglia T1 Hyperintensities on MRI
Erik Valenti, MD
07:00 AM - 05:00 PM EDT Abstract 140 - The stronger the better - diagnostic utility of 7 Tesla MRI in epilepsy patients
Mayur Chalia, MD
07:00 AM - 05:00 PM EDT Abstract 141 - Functional Connectivity and Neurophysiological Evaluation of Patients with Hepatic Cirrhosis
Natália d. Fim Nakao, MD
07:00 AM - 05:00 PM EDT Abstract 142 - Pediatric Phencyclidine (PCP) Intoxication: First Reported Human MRI and EEG Findings
Rebecca Stainman, MD
Faculty Disclosures
David Cantu, PhD Dr. Cantu has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Laurie E. Seltzer, DO Dr. Seltzer has nothing to disclose.
Shaun Hussain, MD Dr. Hussain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MGC Pharma. Dr. Hussain has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix. Dr. Hussain has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Grenwich Biosciences.
Hina N. Dave, MD Dr. Dave has nothing to disclose.
Lilly Fagatele Ms. fagatele has nothing to disclose.
No disclosure on file
Lily Wong-Kisiel, MD, FAAN An immediate family member of Dr. Wong-Kisiel has received intellectual property interests from a discovery or technology relating to health care.
Samden Lhatoo, MD The institution of Dr. Lhatoo has received research support from NIH. Dr. Lhatoo has received intellectual property interests from a discovery or technology relating to health care. Dr. Lhatoo has received publishing royalties from a publication relating to health care.
David C. Diosy, MD Dr. Diosy has nothing to disclose.
Courtney Filliben Ms. Filliben has nothing to disclose.
Kore K. Liow, MD, FACP The institution of Dr. Liow has received research support from UCB. The institution of Dr. Liow has received research support from Livanova. The institution of Dr. Liow has received research support from Biogen. The institution of Dr. Liow has received research support from Novartis. The institution of Dr. Liow has received research support from Eisai. The institution of Dr. Liow has received research support from Engage Therapeutics. The institution of Dr. Liow has received research support from SK Lifescience. The institution of Dr. Liow has received research support from Cerevel. The institution of Dr. Liow has received research support from Xenon. The institution of Dr. Liow has received research support from NeuroDerm. The institution of Dr. Liow has received research support from Avanir. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Acadia. The institution of Dr. Liow has received research support from Prothena. The institution of Dr. Liow has received research support from SAGE. The institution of Dr. Liow has received research support from Annovis. The institution of Dr. Liow has received research support from Cyclerion.
James W. Wheless, MD, FAAP, FAAN Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aquestive. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for LivaNova. Dr. Wheless has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Wheless has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Greenwich. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BioMarin. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix. Dr. Wheless has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelius.
Parul Agarwal No disclosure on file
Victor Biton, MD Dr. Biton has nothing to disclose.
Leslie Siegel, PharmD Ms. Siegel has nothing to disclose.
Jason Viereck, MD, PhD Dr. Viereck has nothing to disclose.
Todd Grinnell, PhD Todd Grinnell, PhD has received personal compensation for serving as an employee of Sunovion Pharmaceuticals Inc..
Sang Kun Lee, MD Prof. Lee has nothing to disclose.
Kristin Bumsch Kristin Bumsch has nothing to disclose.
Soha Sadeghikhah, MD Dr. Sadeghikhah has nothing to disclose.
Sergiu I. Abramovici, MD Dr. Abramovici has nothing to disclose.
Ernesto Aycardi, MD Dr. Aycardi has received personal compensation for serving as an employee of XENON. Dr. Aycardi has received stock or an ownership interest from XENON.
Analia Calle Analia Calle has nothing to disclose.
Amir M. Arain, MD, FAAN Dr. Arain has nothing to disclose.
Carlos Santiago Claverie, MD No disclosure on file
Alejandro Thomson, MD Dr. Thomson has nothing to disclose.
Sushma R. Yerram, MD Dr. Yerram has nothing to disclose.
Alexandra Urban, MD, FAAN Dr. Urban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace. Dr. Urban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Life Science, Inc.
Stella L. Ngo, PhD Dr. Ngo has received personal compensation for serving as an employee of Eisai Inc..
Michael Chez, MD, FAAN Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ucb. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Pharma. Dr. Chez has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eiasai UCB Neurelis aquestiveGW. The institution of Dr. Chez has received research support from Marinus GW Eisai.
Dae W. Seo, MD Dr. Seo has nothing to disclose.
Prathana Hareesh, MBBS Dr. Hareesh has nothing to disclose.
Jody Westbrook Jody Westbrook has received personal compensation for serving as an employee of Invitae. Jody Westbrook has received stock or an ownership interest from Invitae.
Katie L. Bullinger, MD, PhD The institution of Dr. Bullinger has received research support from CDC. The institution of Dr. Bullinger has received research support from NIH. The institution of Dr. Bullinger has received research support from Neuropace. Dr. Bullinger has received publishing royalties from a publication relating to health care.
Jerzy P. Szaflarski, MD, PhD, FAAN Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gidley, Sarli & Marusak, LLP. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea.
Farhad Sahebkar-Moghaddam, MD Dr. Sahebkar-Moghaddam has received personal compensation for serving as an employee of Jazz pharmaceuticals. Dr. Sahebkar-Moghaddam has stock in Jazz pharmaceuticals.
Sheela Toprani, MD, PhD Dr. Toprani has nothing to disclose.
Takafumi Kubota, MD Dr. Kubota has nothing to disclose.
Orrin Devinsky, MD, FAAN Dr. Devinsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for California Cannabis Enterprises. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Privateer Holdings. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Receptor Holdings. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rettco. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Silver Spike. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tevard. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Tilray. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Tevard Biosciences. Dr. Devinsky has received stock or an ownership interest from Engage. Dr. Devinsky has received stock or an ownership interest from Empatica. Dr. Devinsky has received stock or an ownership interest from California Cannabis Enterprises. Dr. Devinsky has received stock or an ownership interest from Empatica. Dr. Devinsky has received stock or an ownership interest from Silver Spike. Dr. Devinsky has received stock or an ownership interest from Docklight Brands. Dr. Devinsky has received stock or an ownership interest from Egg Rock/Papa Barkley. Dr. Devinsky has received stock or an ownership interest from Leafly. Dr. Devinsky has received stock or an ownership interest from Left Coast Ventures. Dr. Devinsky has received stock or an ownership interest from Privateer Holdings. Dr. Devinsky has received stock or an ownership interest from Receptor Holdings. Dr. Devinsky has received stock or an ownership interest from Qstate. The institution of Dr. Devinsky has received research support from GW Pharma. The institution of Dr. Devinsky has received research support from Zogenix. The institution of Dr. Devinsky has received research support from PTC Pharma. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from DOD. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from Epilepsy Foundation. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NIH. The institution of Dr. Devinsky has received research support from NSF. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received publishing royalties from a publication relating to health care.
Christa O'hana S. Nobleza, MD Dr. Nobleza has nothing to disclose.
Lisa Ellison No disclosure on file
Ajaz Sheikh, MD Dr. Sheikh has nothing to disclose.
Júlia Espinosa Júlia Espinosa has nothing to disclose.
Yong-Bum Song, PharmD Dr. Song has nothing to disclose.
R E. Faught, Jr., MD, FAAN Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Faught has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Gideon, Essary, Tardio and Carter PLC, Nashville TN TN law firm. Dr. Faught has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Friedman Dazio and Zulanas Law Firm Birmingham AL. The institution of Dr. Faught has received research support from UCB Pharma.
Ka-Ho Wong The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Carolina B. Maciel, MD, MSCR, FAAN Dr. Maciel has received research support from American Heart Association. Dr. Maciel has received research support from National Institute of Health.
Faisal A. Ibrahim, MD Dr. Ibrahim has nothing to disclose.
Arnold Gammaitoni, PharmD Dr. Gammaitoni has received personal compensation for serving as an employee of Zogenix Inc.. Dr. Gammaitoni has received stock or an ownership interest from Zogenix Inc..
William L. Bell, MD, FAAN Dr. Bell has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Yerridlaw. The institution of Dr. Bell has received research support from Sk Lifescience.
Tirisham Gyang, MD Dr. Gyang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Gyang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich Biosciences. Dr. Gyang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon Therapeutics. Dr. Gyang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Gyang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono.
Masako Matsunaga No disclosure on file
Constanza Luzon Constanza Luzon has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals.
Neel Fotedar, MD Dr. Fotedar has nothing to disclose.
Courtney Wusthoff, MD Dr. Wusthoff has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PRA Health Sciences. Dr. Wusthoff has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for ICON. Dr. Wusthoff has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. Dr. Wusthoff has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Wusthoff has received research support from NIH. The institution of Dr. Wusthoff has received research support from Thrasher Research Fund. Dr. Wusthoff has received publishing royalties from a publication relating to health care.
Larisa Reyderman Larisa Reyderman has nothing to disclose.
Marcia E. Morita-Sherman, MD An immediate family member of Dr. Morita-Sherman has received personal compensation for serving as an employee of Forrester Research. Dr. Morita-Sherman has received personal compensation for serving as an employee of Eisai Inc.. An immediate family member of Dr. Morita-Sherman has stock in Forrester Research. The institution of Dr. Morita-Sherman has received research support from Cleveland Clinic.
Erik Valenti, MD Dr. Valenti has received personal compensation in the range of $0-$499 for serving as a Consultant for LVIS.
Dimitrios Arkilo, MD Dr. Arkilo has received personal compensation for serving as an employee of Sage Therapeutics. Dr. Arkilo has received personal compensation for serving as an employee of Acadia Pharmaceuticals. Dr. Arkilo has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Arkilo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EcoR1. An immediate family member of Dr. Arkilo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. An immediate family member of Dr. Arkilo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medtronic. Dr. Arkilo has stock in Takeda Pharmaceuticals. Dr. Arkilo has stock in Acadia Pharmaceuticals. Dr. Arkilo has stock in Sage Therapeutics.
Estevo Santamarina The institution of Estevo Santamarina has received research support from INSTITUTO CARLOS III - GOVERNMENT ENTITY IN SPAIN.
Hai Chen, MD, PhD Dr. Chen has nothing to disclose.
Mahnaz Asgharnejad, PharmD Mahnaz Asgharnejad, PharmD has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Mahnaz Asgharnejad, PharmD has stock in GlaxoSmithKline. Mahnaz Asgharnejad, PharmD has stock in Takeda Pharmaceuticals.
Dario J. Englot No disclosure on file
Mustafa Al-Chalabi, DO Dr. Al-Chalabi has nothing to disclose.
Nancy R. Foldvary-Schaefer, DO, FAAN Dr. Foldvary-Schaefer has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Jazz. The institution of Dr. Foldvary-Schaefer has received research support from Suven. The institution of Dr. Foldvary-Schaefer has received research support from Takeda. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care. Dr. Foldvary-Schaefer has received publishing royalties from a publication relating to health care.
Iftekhar Ahmed, MD, PC, FAAN Dr. Ahmed has nothing to disclose.
J. H. Harvey, DO Dr. Harvey has received personal compensation for serving as an employee of RSC Diagnostics. The institution of Dr. Harvey has received research support from GW Pharmaceuticals. The institution of Dr. Harvey has received research support from Cerevel Pharmaceuticals. The institution of Dr. Harvey has received research support from UCB Pharmaceuticals.
Mason Leeman-Markowski, MD No disclosure on file
Olivia Thornburg Olivia Thornburg has nothing to disclose.
Irene L. Katzan, MD Dr. Katzan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . The institution of Dr. Katzan has received research support from TEVA Pharmaceuticals.
Jocelyn B. Lorenzo, MD Dr. Lorenzo has nothing to disclose.
Josephine Gutierrez, MD No disclosure on file
L J. Greenfield, Jr., MD, PhD, FAAN Dr. Greenfield has received publishing royalties from a publication relating to health care.
Rebecca O'Dwyer, MD Dr. O'Dwyer has nothing to disclose.
Stephen Hantus, MD Dr. Hantus has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Hantus has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB.
Gregory L. Krauss, MD Dr. Krauss has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle. Dr. Krauss has received stock or an ownership interest from EpiWatch.
Churl-Su Kwon, MBBS Dr. Kwon has nothing to disclose.
Joana Moreira Joana Moreira has received personal compensation for serving as an employee of BIAL.
Joseph Wiedemer Mr. Wiedemer has nothing to disclose.
Eugen Trinka Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Böhringer Ingelheim. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Everpharma. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Liva-Nova. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Newbridge. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Marinus. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Eugen Trinka has received research support from Austrian Science Fund (FWF). Eugen Trinka has received research support from Österreichische Nationalbank. Eugen Trinka has received research support from European Union. Eugen Trinka has received research support from GSK. Eugen Trinka has received research support from Biogen. Eugen Trinka has received research support from Eisai. Eugen Trinka has received research support from Novartis. Eugen Trinka has received research support from Red Bull. Eugen Trinka has received research support from Bayer. Eugen Trinka has received research support from UCB. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a other with Neuroconsult Ges.m.b.H..
Vineet Punia, MD Dr. Punia has nothing to disclose.
Jeremy D. Slater, MD, FAAN Dr. Slater has received personal compensation for serving as an employee of Stratus. Dr. Slater has stock in Zeto LLC.
Wendy Chen, MD Dr. Chen has nothing to disclose.
Kan Ding, MD The institution of Dr. Ding has received research support from National Institute of Aging. The institution of Dr. Ding has received research support from NINDS.
Christopher P. Robinson, DO Dr. Robinson has nothing to disclose.
Rebecca Stainman, MD Dr. Stainman has nothing to disclose.
Andrea R. Lowden, MD Dr. Lowden has nothing to disclose.
Corinne Allas No disclosure on file
Diosely C. Silveira, MD, PhD Dr. Silveira has nothing to disclose.
Bassel W. Abou-Khalil, MD, FAAN The institution of Dr. Abou-Khalil has received research support from Cerevel. The institution of Dr. Abou-Khalil has received research support from Xenon. The institution of Dr. Abou-Khalil has received research support from Otsuka. The institution of Dr. Abou-Khalil has received research support from UCB. The institution of Dr. Abou-Khalil has received research support from SK LIfe Science. The institution of Dr. Abou-Khalil has received research support from Neuroelectrics.
Dennis J. Dlugos, MD Dr. Dlugos has received research support from NIH. The institution of Dr. Dlugos has received research support from The Epilepsy Study Consortium.
David G. Vossler, MD, FAAN Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $0-$499 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Longboard Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Xenon Pharmaceuticals. Dr. Vossler has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Science. The institution of Dr. Vossler has received research support from SK Life Science. The institution of Dr. Vossler has received research support from Xenon Pharmaceuticals. The institution of Dr. Vossler has received research support from Longboard Pharmaceuticals.
Abdullah Al Sawaf, MD Dr. Al Sawaf has nothing to disclose.
Christian Brandt, MD Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW. Dr. Brandt has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Desitin. Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arvelle. Dr. Brandt has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Brandt has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix. Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW. Dr. Brandt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Arvelle. The institution of Dr. Brandt has received research support from Rubin-Stiftung. Dr. Brandt has received publishing royalties from a publication relating to health care.
Musab Ali, MD Dr. Ali has nothing to disclose.
Steven Gangloff, MD Dr. Gangloff has nothing to disclose.
Jessica Falco-Walter, MD Dr. Falco-Walter has nothing to disclose.
Andrew Lin, MD Dr. Lin has nothing to disclose.
Sohail A. Kamrudin, DO Dr. Kamrudin has nothing to disclose.
Trudy Pang, MD Dr. Pang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Stratus an Alliance Company.
Louis Ferrari Louis Ferrari has received personal compensation for serving as an employee of SK Life science.
Salam M. Nasralla, MD Dr. Nasralla has nothing to disclose.
Marian P. LaMonte, MD, MSN, FAAN Dr. LaMonte has nothing to disclose.
Sean Hwang, MD Dr. Hwang has nothing to disclose.
Eric Segal, MD Dr. Segal has received personal compensation for serving as an employee of Lundbeck. Dr. Segal has received personal compensation for serving as an employee of Eisai. Dr. Segal has received personal compensation for serving as an employee of Neurelis. Dr. Segal has received personal compensation for serving as an employee of Zogenix. Dr. Segal has received personal compensation for serving as an employee of Aquestive. Dr. Segal has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. Segal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. Dr. Segal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Segal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwhich Bioscience. Dr. Segal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Greenwhich Bioscience. Dr. Segal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis.
Robert T. Wechsler, MD, PhD, FAAN The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Otsuka. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Science. The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Engage. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Jazz. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. The institution of Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sunovion. The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eliem. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epalex. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engrail. The institution of Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Equilibre. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Raport. The institution of Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona. Dr. Wechsler has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Sunovion. Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Greenwich. Dr. Wechsler has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai. Dr. Wechsler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aquestive. Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Science. Dr. Wechsler has a non-compensated relationship as a Board President with Epilepsy Foundation of Idaho that is relevant to AAN interests or activities.
Dietrich Haubenberger, MD, FAAN Dr. Haubenberger has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc. Dr. Haubenberger has stock in Neurocrine Biosciences. Dr. Haubenberger has a non-compensated relationship as a Member of the Board with American Society for Experimental Neurotherapeutics that is relevant to AAN interests or activities.
Amanda Bingaman Ms. Bingaman has nothing to disclose.
Stephanie C. Murti, DO Ms. Murti has nothing to disclose.
Yao Cheng, MBBS Dr. Cheng has nothing to disclose.
Paul V. Motika, MD Dr. Motika has nothing to disclose.
Elizabeth Thiele, MD Dr. Thiele has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GW Pharma/Jazz. Dr. Thiele has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for zogenix/UCB. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for nobelpharma. An immediate family member of Dr. Thiele has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Thor labs. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for takeda. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for livanova. Dr. Thiele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Azurity. Dr. Thiele has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Marinus Pharmaceuticals. The institution of Dr. Thiele has received research support from GW Pharma/Jazz. The institution of Dr. Thiele has received research support from Zogenix/UCB. The institution of Dr. Thiele has received research support from Stoke Therapeutics.
Monica J. Goodman Monica Goodman has nothing to disclose.
Dinesh Kumar No disclosure on file
Nicholas Thompson No disclosure on file
Noam Butterfield, PhD Dr. Butterfield has received personal compensation for serving as an employee of Xenon Pharmaceuticals.
Adam De Havenon, MD, FAAN Dr. De Havenon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Michael Kentris, DO Dr. Kentris has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology.
Niravkumar Barot, MD Dr. Barot has nothing to disclose.
Madeline C. Fields, MD Dr. Fields has nothing to disclose.
Helena Gama Helena Gama has received personal compensation for serving as an employee of Bial-Portela & Cª S.A..
Shawniqua Williams Roberson, MD Dr. Williams Roberson has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Today. The institution of Dr. Williams Roberson has received research support from the National Institute on Aging. The institution of Dr. Williams Roberson has received research support from Brain & Behavior Research Foundation. Dr. Williams Roberson has received personal compensation in the range of $0-$499 for serving as a Reviewer with the National Institutes of Health. Dr. Williams Roberson has received personal compensation in the range of $0-$499 for serving as a Visiting Speaker with University of Pennsylvania. Dr. Williams Roberson has received personal compensation in the range of $0-$499 for serving as a Faculty Speaker with the International Symposium for Intensive Care and Emergency Medicine.
Kanika Sharma, MD Dr. Sharma has nothing to disclose.
Martin Rabe, MSc Martin Rabe, M.Sc. has received personal compensation for serving as an employee of Eisai Inc.
Trevor J. Resnick, MD Dr. Resnick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Resnick has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for supernus. Dr. Resnick has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion.
Alexander Crossley Mr. Crossley has nothing to disclose.
Saien Lai, MD Dr. Lai has nothing to disclose.
Brian J. Hanrahan, MD Dr. Hanrahan has received personal compensation for serving as an employee of Nowyouknow Neuro.
Guido D. Vazquez II, PhD Dr. Vazquez has nothing to disclose.
Ryan Hays, MD, MBA, FAES, FAAN Dr. Hays has nothing to disclose.
Olivia Groover, MD Dr. Groover has nothing to disclose.
Evren Burakgazi, MD Dr. Burakgazi has nothing to disclose.
Ronald Alvarado Dyer, MD Dr. Alvarado Dyer has nothing to disclose.
Patrick K. Kwan, MD, PhD No disclosure on file
Karina A. Gonzalez Otarula, MD Dr. Gonzalez Otarula has nothing to disclose.
Veronica Campanille, MD No disclosure on file
Hugh D. Simpson, MD Dr. Simpson has nothing to disclose.
Marisara Dieppa, MD Dr. Dieppa has nothing to disclose.
Patricia E. Penovich, MD, FAAN Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Engage therapeutics. Dr. Penovich has received personal compensation in the range of $0-$499 for serving as a Consultant for LVIS. Dr. Penovich has received personal compensation in the range of $0-$499 for serving as a Consultant for Monteris. Dr. Penovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Therapeutics. Dr. Penovich has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Penovich has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Greenwich. Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK Biosciences. Dr. Penovich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Penovich has a non-compensated relationship as a Comittee Member with American Epilepsy Society that is relevant to AAN interests or activities.
Jocelyn Y. Cheng, MD, FAAN Dr. Cheng has received personal compensation for serving as an employee of Eisai Inc.
Wui Ho Wui Ho has nothing to disclose.
Anika Morgado Ms. Morgado has nothing to disclose.
Hernan Nicolas Lemus Esquivel, MD Dr. Lemus Esquivel has nothing to disclose.
Nicholas Janocko, MD Dr. Janocko has nothing to disclose.
Toufic Fakhoury, MD Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB pharma. Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai . Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aquestive therapeutics. Dr. Fakhoury has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Fakhoury has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Fakhoury has received research support from Xenon. The institution of Dr. Fakhoury has received research support from Takeda.
Hugh Jiwoong Lee Hugh Jiwoong Lee has nothing to disclose.
Chokri A. Mhiri, MD Prof. Mhiri has received personal compensation for serving as an employee of Hikma. Prof. Mhiri has received personal compensation for serving as an employee of Sanofi Genzyme. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Prof. Mhiri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche.
Tracey Cho, MD, FAAN Dr. Cho has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. The institution of an immediate family member of Dr. Cho has received research support from NIH. Dr. Cho has received publishing royalties from a publication relating to health care.
Tina Liu, MD Dr. Liu has nothing to disclose.
Brenda Auffinger, MD Dr. Auffinger has nothing to disclose.
Ana Suller Marti, MD Dr. Suller Marti has nothing to disclose.
Sang-Ahm Lee, MD Dr. Lee has nothing to disclose.
Alfredo Thomson, MD Dr. Thomson has nothing to disclose.
Deepti Chrusciel, MD Dr. Chrusciel has nothing to disclose.
Mauricio F. Farez, MD Dr. Farez has nothing to disclose.
Kevan VanLandingham, MD, PhD, FAAN Dr. VanLandingham has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. VanLandingham has received stock or an ownership interest from Greenwich Biosciences.
Taha Gholipour, MD Dr. Gholipour has nothing to disclose.
Chelsea Robalino No disclosure on file
Vicente Villanueva No disclosure on file
Sunita Dergalust, PharmD Ms. Dergalust has nothing to disclose.
Diane Teagarden, NP Ms. Teagarden has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for livaNova. Ms. Teagarden has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuropace.
Babak Razavi, MD, PhD Dr. Razavi has stock in CortexXus. The institution of Dr. Razavi has received research support from Neuropace.
Anil Chimakurthy, MD Dr. Chimakurthy has nothing to disclose.
Amir Karimi No disclosure on file
Jon T. Willie, MD, PhD Jon T. Willie, MD, PhD has received personal compensation in the range of $0-$499 for serving as a Consultant for AiM Medical. Jon T. Willie, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Medtronic. Jon T. Willie, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuropace.
Ioannis Karakis, MD, FAAN Dr. Karakis has received personal compensation for serving as an employee of Emory University School of Medicine. Dr. Karakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Karakis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GSK. Dr. Karakis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epitel. Dr. Karakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Karakis has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Hill Ward Henderson.
Danielle S. McDermott, MD The institution of Dr. McDermott has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Marinus Pharmaceuticals . Dr. McDermott has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK biosciences .
Rachel Gorenflo Rachel Gorenflo has nothing to disclose.
Andrew Trigg Andrew Trigg has received personal compensation for serving as an employee of Adelphi Values.
Ibrahim Mustafa, MD Dr. Mustafa has nothing to disclose.
Mansi B. Parekh, PhD Dr. Parekh has received personal compensation for serving as an employee of Neurona Therapeutics.
Celene Grayson, PhD Dr. Grayson has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Grayson has received stock or an ownership interest from Xenon Pharmaceuticals Inc..
Vicki A. Ramsey-Williams, MD, PhD Dr. Ramsey-Williams has nothing to disclose.
Rahul Khanna, MBBS Dr. Khanna has nothing to disclose.
Ahmad A. Ballout, MD Dr. Ballout has nothing to disclose.
Maria J. Bruzzone, MD Dr. Bruzzone has nothing to disclose.
John M. Schreiber, MD Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xenon. Dr. Schreiber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zogenix. The institution of Dr. Schreiber has received research support from Dravet Syndrome Foundation.
Hans Klein, PhD Hans Klein has received personal compensation for serving as an employee of Stratus.
Jordan Seliger No disclosure on file
John Thompson John Thompson has nothing to disclose.
Mohamed Tom, MD Dr. Tom has received personal compensation for serving as an employee of Allegheny General Hospital . Dr. Tom has received personal compensation for serving as an employee of Mercy Hospital St. Louis .
Jerome Engel, Jr., MD, PhD, FAAN Dr. Engel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerebel. Dr. Engel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Engel has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink. Dr. Engel has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Steven Barris. Dr. Engel has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Cutler Law Firm. Dr. Engel has received publishing royalties from a publication relating to health care. Dr. Engel has received publishing royalties from a publication relating to health care. Dr. Engel has received publishing royalties from a publication relating to health care. Dr. Engel has received publishing royalties from a publication relating to health care.
Hongyan Li, MD, PhD, FAAN Dr. Li has nothing to disclose.
Peter B. Forgacs, MD Dr. Forgacs has received personal compensation for serving as an employee of OVID Therapeutics Inc. Dr. Forgacs has received stock or an ownership interest from OVID Therapeutics Inc.
Mohanad A. AlGaeed, MD Dr. ALGaeed has nothing to disclose.
Page B. Pennell, MD, FAAN The institution of Dr. Pennell has received research support from NIH. The institution of an immediate family member of Dr. Pennell has received research support from Department of Defense. The institution of an immediate family member of Dr. Pennell has received research support from Environmental Protection Agency. The institution of an immediate family member of Dr. Pennell has received research support from NIH. The institution of an immediate family member of Dr. Pennell has received research support from Advanced Energy Consortium. Dr. Pennell has received publishing royalties from a publication relating to health care.
Enrique Carrazana Enrique Carrazana has received personal compensation for serving as an employee of Neurelis. Enrique Carrazana has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Neurelis, Alexza, Zogenix. Enrique Carrazana has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Hawaii-Biotech, CND Life Sciences. Enrique Carrazana has stock in Neurelis, Marinus, .
Rodrigo Zepeda Garcia, MD The institution of Dr. Zepeda Garcia has received research support from NIH.
James D. Triplett, MBBS Dr. Triplett has nothing to disclose.
R. E. Ramsay, MD Dr. Ramsay has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alliance Family of Companies. Dr. Ramsay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. Dr. Ramsay has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Ramsay has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Ramsay has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK Life Sci.
Patrick Kwan Patrick Kwan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EDUCOM SPA. Patrick Kwan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Patrick Kwan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. The institution of Patrick Kwan has received research support from UCB. The institution of Patrick Kwan has received research support from Eisai.
Robyn Busch No disclosure on file
Cynthia L. Harden, MD Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc.. Dr. Harden has received intellectual property interests from a discovery or technology relating to health care.
Kimford J. Meador, MD, FAAN The institution of Dr. Meador has received research support from NIH. The institution of Dr. Meador has received research support from Eisai. The institution of Dr. Meador has received research support from Medtronics. The institution of Dr. Meador has received research support from The Epilepsy Consortium.
Sidra Saleem, MD Dr. Saleem has nothing to disclose.
Omar Nofal, MD Dr. Nofal has nothing to disclose.
Shafali Jeste, MD, FAAN Dr. Jeste has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals. Dr. Jeste has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN Continuum. The institution of Dr. Jeste has received research support from NIH. The institution of Dr. Jeste has received research support from DoD. The institution of Dr. Jeste has received research support from Dup15q Alliance.
Alise K. Carlson, MD Dr. Carlson has received research support from Biogen (fellowship grant 16696-P-FEL).
Amitabh Dash, MD Amitabh Dash, MD has nothing to disclose.
Marina K. Alvim Dr. Alvim has nothing to disclose.
Ahmed Abbas, MD Dr. Abbas has nothing to disclose.
Lauren B. Fine, PA Mrs. Fine has nothing to disclose.
Julia Bodnya, MD Dr. Bodnya has nothing to disclose.
Bradley Lega, MD The institution of Bradley Lega has received research support from NIH.
Vaclav Kremen Vaclav Kremen has nothing to disclose.
Dave F. Cook No disclosure on file
Claude G. Wasterlain, MD, FAAN The institution of Dr. Wasterlain has received research support from Eisai. Dr. Wasterlain has received publishing royalties from a publication relating to health care.
Imad M. Najm, MD Dr. Najm has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai Inc. Dr. Najm has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Inc. Dr. Najm has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai Inc.
Clarissa L. Yasuda, MD, PhD Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for LIBBS. Prof. Yasuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBOTT. Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for LIBBS.
Abril Marone, MD Dr. Marone has nothing to disclose.
santiago Claverie santiago Claverie has nothing to disclose.
Marc Kamin, MD Dr. Kamin has received personal compensation for serving as an employee of SK LIFE SCIENCE INC.
Alexander G. Doyle, MD Dr. Doyle has nothing to disclose.
Marie C. Eugene, DO Dr. Eugene has nothing to disclose.
Niyatee Samudra, MD Dr. Samudra has nothing to disclose.
Michael C. Irizarry, MD Dr. Irizarry has received personal compensation for serving as an employee of Eisai, Inc..
Manuel Toledo No disclosure on file
Pouria A. Koushesh Mr. Koushesh has nothing to disclose.
Ammar Tarabichi, MD Dr. Tarabichi has nothing to disclose.
Mindy Grall, PhD, NP Ms. Grall has received personal compensation for serving as an employee of Supernus Pharmaceuticals. Ms. Grall has stock in Supernus.
Kourosh Rezania, MD, FAAN Dr. Rezania has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Akcea. Dr. Rezania has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alnylam.
Ahyuda Oh, PhD Dr. Oh has nothing to disclose.
Fabio Ikedo Fabio Ikedo has received personal compensation for serving as an employee of Bial.
Elizabeth Cunningham No disclosure on file
Deepak K. Lachhwani, MD, FAAN The institution of Dr. Lachhwani has received research support from ICON Clinical Research LLC.
Caroline Kim, Pharmacist Caroline Kim has nothing to disclose.
Dileep R. Nair, MD Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NeuroPace. Dr. Nair has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for NeuroPace.
Robert Gross No disclosure on file
Ian T. Coulter, MD Dr. Coulter has nothing to disclose.
Alejandro Salah, MD, PhD, MBA, MHA Dr. Salah has nothing to disclose.
Uma Menon, MD, MBA, FAAN Dr. Menon has nothing to disclose.
Anna McDonnell Mrs. McDonnell has nothing to disclose.
Mohammed A. ElSherif, MD, PhD, FAAN Dr. ElSherif has nothing to disclose.
Ricardo D. Bernater No disclosure on file
Patrick Landazuri, MD, FAAN Dr. Landazuri has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Federal Public Defender - District of Kansas. Dr. Landazuri has received publishing royalties from a publication relating to health care.
Katherine Werbaneth, MD Dr. Werbaneth has nothing to disclose.
Faddi G. Saleh Velez, MD Dr. Saleh Velez has nothing to disclose.
Majed Alzahrany, MBBS Dr. Alzahrany has nothing to disclose.
Asia Payne, MD Ms. Payne has nothing to disclose.
Sotiris G. Mitropanopoulos, MD Dr. Mitropanopoulos has nothing to disclose.
Yazan Nofal, MD Dr. Nofal has nothing to disclose.
Rebecca E. Matthews, MD Dr. Matthews has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Matthews has received personal compensation in the range of $10,000-$49,999 for serving as a Speaker with Penry Epilepsy Programs.
Haley Phillips, MD Dr. Phillips has nothing to disclose.
Cory R. Nicholas, PhD Dr. Nicholas has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Nicholas has stock in Neurona Therapeutics. Dr. Nicholas has received intellectual property interests from a discovery or technology relating to health care.
Catherine Priest No disclosure on file
Helaina Lehrer, MD Dr. Lehrer has nothing to disclose.
Jeffrey W. Britton, MD, FAAN Dr. Britton has received personal compensation in the range of $0-$499 for serving as a Online course with American Clinical Neurophysiology Society.
Luis Fuentealba No disclosure on file
Amy Nowacki No disclosure on file
Luis Magalhaes Luis Magalhaes has received personal compensation for serving as an employee of BIAL-Portela & Cª, S.A..
Michael R. Sperling, MD, FAAN Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium .
Nataliya Pyatka, MD Dr. Pyatka has nothing to disclose.
Robert Flamini, MD Dr. Flamini has received personal compensation in the range of $0-$499 for serving as a Consultant for Biocodex. Dr. Flamini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Flamini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals.
Siddhika Sreenivasan No disclosure on file
Tze-Chiang Meng Tze-Chiang Meng has received personal compensation for serving as an employee of Proximagen, LLC. An immediate family member of Tze-Chiang Meng has a non-compensated relationship as a Stockholder with Abbott Laboratories that is relevant to AAN interests or activities. An immediate family member of Tze-Chiang Meng has a non-compensated relationship as a Stockholder with Johnson & Johnson that is relevant to AAN interests or activities. An immediate family member of Tze-Chiang Meng has a non-compensated relationship as a Stockholder with Medtronic that is relevant to AAN interests or activities. Tze-Chiang Meng has a non-compensated relationship as a Stockholder with 3M that is relevant to AAN interests or activities.
Ian Miller, MD Dr. Miller has received personal compensation for serving as an employee of Marinus Pharmaceuticals. Dr. Miller has stock in Marinus Pharmaceuticals.
Brad K. Kamitaki, MD Dr. Kamitaki has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brown and Brown Absence Services Group. The institution of Dr. Kamitaki has received research support from American Epilepsy Society. The institution of Dr. Kamitaki has received research support from New Jersey Health Foundation.
Fatima Zuberi, MD, BA Fatima Zuberi has nothing to disclose.
Vishal Shah, MBBS Dr. Shah has nothing to disclose.
Steven P. Sparagana, MD, FAAN Dr. Sparagana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich Biosciences. Dr. Sparagana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nobelpharma. The institution of Dr. Sparagana has received research support from Greenwich Biosciences. The institution of Dr. Sparagana has received research support from Tuberous Sclerosis Alliance. The institution of Dr. Sparagana has received research support from Novartis. Dr. Sparagana has a non-compensated relationship as a Professional Advisory Board Member, committee member with Tuberous Sclerosis Alliance that is relevant to AAN interests or activities.
Luiz E. Betting Dr. Betting has nothing to disclose.
Richard McLachlan, MD No disclosure on file
Salman Tarique, MD Dr. Tarique has nothing to disclose.
John M. Stern, MD, FAAN Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Science. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharma. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for LivaNova. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Stern has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Stern has stock in DEARhealth. Dr. Stern has stock in Ceribell. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care.
Kyra Curtis, MD Ms. Curtis has nothing to disclose.
J Renfroe, MD Dr. Renfroe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage Therapeutics. Dr. Renfroe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Renfroe has received intellectual property interests from a discovery or technology relating to health care.
Mark Agostini, MD Dr. Agostini has nothing to disclose.
Aakriti Kothiwal Dr. Kothiwal has nothing to disclose.
Kamil Detyniecki, MD Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aquestive. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Detyniecki has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich.
Anup D. Patel, MD, FAAN The institution of Dr. Patel has received research support from Stoke. The institution of Dr. Patel has received research support from NIH. The institution of Dr. Patel has received research support from PCORI. Dr. Patel has received personal compensation in the range of $5,000-$9,999 for serving as a Webinar Development with Medscape. Dr. Patel has a non-compensated relationship as a Committee member with AAN that is relevant to AAN interests or activities. Dr. Patel has a non-compensated relationship as a President Board of Directors with Pediatric Epilepsy Research Foundation that is relevant to AAN interests or activities.
Ali A. Fadhil, MD Dr. Fadhil has nothing to disclose.
Anne M. Comi, MD Dr. Comi has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Greenwich Biosciences. The institution of Dr. Comi has received research support from Greenwich Biosciences. The institution of Dr. Comi has received research support from Celebrate Hope Foundation. The institution of Dr. Comi has received research support from Faneca 66 Foundation. Dr. Comi has received intellectual property interests from a discovery or technology relating to health care.
Jean E. Cibula, MD, FAAN Dr. Cibula has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medical Information Group. Dr. Cibula has received stock or an ownership interest from Merck. Dr. Cibula has received stock or an ownership interest from 3M. Dr. Cibula has received stock or an ownership interest from Steris. Dr. Cibula has received stock or an ownership interest from Baxter. The institution of Dr. Cibula has received research support from UCB Pharma.
Anto Bagic, MD, PhD Dr. Bagic has nothing to disclose.
Tony Wu, MD, PhD Dr. Wu has nothing to disclose.
Jay Salpekar No disclosure on file
Abby Begezda, MD Ms. Begezda has nothing to disclose.
Prasannakumar K. Gajera, MBBS Prasannakumar Gajera has nothing to disclose.
Daniel C. Tarquinio, DO The institution of Dr. Tarquinio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis.
Biju Gopalakrishnan, MD, MBBS, DM Dr. Gopalakrishnan has nothing to disclose.
Sameer Sharma, MD, MBBS Dr. Sharma has nothing to disclose.
Ramsha A. Bhutta, MD Dr. Bhutta has nothing to disclose.
Vibhor Krishna No disclosure on file
Fawad A. Khan, MD The institution of Dr. Khan has received research support from Amgen .
Carla F. Bolano Diaz, MD Dr. Bolano Diaz has nothing to disclose.
Wesley Kerr, MD, PhD Dr. Kerr has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Lifesciences. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EpiTel. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerebral Therapeutics. Dr. Kerr has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. The institution of Dr. Kerr has received research support from NINDS. The institution of Dr. Kerr has received research support from American Epilepsy Society. The institution of Dr. Kerr has received research support from American Academy of Neurology. Dr. Kerr has received publishing royalties from a publication relating to health care.
Yara Mikhaeil-Demo, MD The institution of Dr. Mikhaeil-Demo has received research support from DOD/CURE TBI Consortium, Grant W81XWH . The institution of Dr. Mikhaeil-Demo has received research support from Illinois Department of Human Services (IDHS) Grant .
Nazanin Sheibani, MD Dr. Sheibani has nothing to disclose.
Alison Cutts Alison Cutts has received personal compensation for serving as an employee of Xenon Pharmaceuticals. Alison Cutts has received stock or an ownership interest from Xenon Pharmaceuticals.
Hyunmi Kim, MD Dr. Kim has nothing to disclose.
Wentao Li, MD Dr. Li has nothing to disclose.
Russell P. Saneto, DO, PhD Dr. Saneto has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for REATA. Dr. Saneto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GW Pharmaceuticals. The institution of Dr. Saneto has received research support from NIH. The institution of Dr. Saneto has received research support from Zogenix. The institution of Dr. Saneto has received research support from GW Pharmaceuticals.
Parakash Pratibhu, MD Dr. Pratibhu has nothing to disclose.
Rohit Das, MD, FAAN Dr. Das has received personal compensation for serving as an employee of Concentra.
Lynn Liu, MD, FAAN Dr. Liu has stock in Pfizer.
Rohit Shankar Rohit Shankar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Rohit Shankar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. The institution of Rohit Shankar has received research support from eisai. The institution of Rohit Shankar has received research support from UCB. The institution of Rohit Shankar has received research support from LivaNova. The institution of Rohit Shankar has received research support from GW pharma. The institution of Rohit Shankar has received research support from NIHR. The institution of Rohit Shankar has received research support from SBRI.
Aissata Diawara, MD Dr. Diawara has nothing to disclose.
Michael C. Smith, MD, FAAN Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SK Lifesciences. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SK Lifesciences .
Cecil D. Hahn, MD Dr. Hahn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda Pharmaceuticals. Dr. Hahn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Hahn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Holberg EEG. Dr. Hahn has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. Dr. Hahn has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for various legal firms. Dr. Hahn has received publishing royalties from a publication relating to health care. Dr. Hahn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with CADTH.
Jorge G. Burneo, MD, MSPH, FAAN Dr. Burneo has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier, Clinical Neurology and Neurosurgery Journal. Dr. Burneo has received research support from The Jack Cowin Endowed Chair in Epilepsy Research. Dr. Burneo has received publishing royalties from a publication relating to health care.
Harshad Ladha, MD Dr. Ladha has nothing to disclose.
Pravin George, DO Dr. George has nothing to disclose.
Miguel Arevalo Astrada Miguel Arevalo Astrada has nothing to disclose.
Masud Seyal, MD, PhD, FAAN Dr. Seyal has nothing to disclose.
Manjot Grewal, MD Dr. Grewal has nothing to disclose.
Jillian Rosengard, MD Dr. Rosengard has nothing to disclose.
Guadalupe Fernandez-Baca Vaca, MD Dr. Fernandez-Baca Vaca has nothing to disclose.
Cynthia Guerra Cynthia Guerra has received personal compensation for serving as an employee of Neurelis, Inc. Cynthia Guerra has received stock or an ownership interest from Neurelis Inc.
Katrina Roberto, MD Dr. Roberto has nothing to disclose.
Aida Risman, MD Dr. Risman has nothing to disclose.
Anne T. Berg, PhD Dr. Berg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Berg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Berg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Encoded. Dr. Berg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biomarin. The institution of Dr. Berg has received research support from FamilieSCN2A Foundation.
Anum H. Riaz, MD Dr. Riaz has nothing to disclose.
David W. Loring, PhD, FAAN Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. Dr. Loring has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE. The institution of Dr. Loring has received research support from NIH. Dr. Loring has received publishing royalties from a publication relating to health care.
Hira Pervez, MD, MBBS Dr. Pervez has nothing to disclose.
Gayane R. Melikyan, MD, FAAN Dr. Melikyan has nothing to disclose.
Sima I. Patel, MD Dr. Patel has nothing to disclose.
Chang Shek Kwan, MD Dr. Kwan has nothing to disclose.
Steven C. Schachter, MD, FAAN Dr. Schachter has received personal compensation in the range of $0-$499 for serving as a Consultant for Supernus Pharmaceuticals. Dr. Schachter has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Schachter has received intellectual property interests from a discovery or technology relating to health care. Dr. Schachter has received publishing royalties from a publication relating to health care. Dr. Schachter has received publishing royalties from a publication relating to health care.
Jose A. Montes-Rivera, MD, FAAN Dr. Montes-Rivera has nothing to disclose.
Arooj Kohli, MD Dr. Kohli has nothing to disclose.
Carlos Perdomo No disclosure on file
Busranur Agac, MD Dr. Agac has nothing to disclose.
Prashant K. Rai, MD Dr. Rai has nothing to disclose.
Mayur Chalia, MD Dr. Chalia has nothing to disclose.
Lara Jehi, MD Dr. Jehi has nothing to disclose.
Gustavo A. Patino, MD, PhD Dr. Patino has received publishing royalties from a publication relating to health care. Dr. Patino has received personal compensation in the range of $0-$499 for serving as a project mentor with Manning Publications.
Sasha Alick-Lindstrom, MD, FACNS, FAES, FAAN Dr. Alick-Lindstrom has nothing to disclose.
Melinda S. Martin, PhD Dr. Martin has received personal compensation for serving as an employee of UCB. Dr. Martin has received stock or an ownership interest from UCB.
Patrick Arraj Mr. Arraj has nothing to disclose.
Paul Lyons, MD Dr. Lyons has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals .
Atul Maheshwari, MD Dr. Maheshwari has nothing to disclose.
Kelsey Sewell Kelsey Sewell has nothing to disclose.
Jamie A. Simpson Mr. Simpson has nothing to disclose.
Ronald L. Thibert, DO Dr. Thibert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ovid Pharmaceuticals.
Alicia Gonzalez-Martinez, MD Dr. Gonzalez-Martinez has nothing to disclose.
Guiyun Wu, MD Dr. Wu has nothing to disclose.
Jafar Hashem, MD Dr. Hashem has nothing to disclose.
Natália d. Fim Nakao, MD Natália Fim Nakao has nothing to disclose.
Pavel Klein, MD, FAAN The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Aquestive. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Sience. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alliance. The institution of Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle Therapeutics. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Aquestive. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eisai. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sunovion. Dr. Klein has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for PrevEp. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Fenwick . Dr. Klein has received research support from DOD/CURE.
Manoj Malhotra, MD Dr. Malhotra has received personal compensation for serving as an employee of Eisai.
Ifrah Zawar, MD The institution of Dr. Zawar has received research support from Alzheimer's association. The institution of Dr. Zawar has received research support from American epilepsy society .
Seyed M. Mirsattari, MD, PhD, FRCPC Dr. Mirsattari has nothing to disclose.
Lynn D. Kramer, MD, FAAN Dr. Kramer has received personal compensation for serving as an employee of Eisai Inc.
Francis M. Filloux, MD Dr. Filloux has nothing to disclose.
Takamichi Yamamoto, MD, PhD, FAES Dr. Yamamoto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Yamamoto has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Daiichi-Sankyo.
Taoufik Alsaadi, MD, FAAN Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilli. Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NewBridge. Dr. Alsaadi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilli. Dr. Alsaadi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for NewBridge. Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Hikma. Dr. Alsaadi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Alsaadi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
Ji-Yeoun Yoo, MD No disclosure on file
Jenan N. Shukry, MD Dr. Shukry has nothing to disclose.
Blake Newman, MD Dr. Newman has nothing to disclose.
Ryan Edbert Husni Ryan Edbert Husni has received personal compensation for serving as an employee of Eisai, Co. Ltd. Ryan Edbert Husni has received personal compensation in the range of $500-$4,999 for serving as a Foreign Scholar with Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT).
Denise Li, MD Dr. Li has nothing to disclose.
Wendyl J. D'Souza, MD, MBChB Dr. D'Souza has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LivaNova, Eisai, UCB, Tilray. Dr. D'Souza has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB Pharma, Eisai Pharmaceutical. Dr. D'Souza has stock in Epiminder. The institution of Dr. D'Souza has received research support from UCB Pharma. The institution of Dr. D'Souza has received research support from Eisai Pharmaceutical.
Christopher R. Newey, DO Dr. Newey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bard.
Arkady Nisman, PharmD Dr. Nisman has received personal compensation for serving as an employee of SK Life Science, Inc. Dr. Nisman has a non-compensated relationship as a Director, Medical Information with SK Life Science, Inc. that is relevant to AAN interests or activities.
Clio A. Rubinos, MD Dr. Rubinos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Qualtrics Inc. Dr. Rubinos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Azurity Pharmaceuticals. Dr. Rubinos has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for American Epilepsy Society . Dr. Rubinos has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Marinus Pharmaceutical. Dr. Rubinos has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for American Epilepsy Society . The institution of Dr. Rubinos has received research support from University of North Carolina .
Navkiranjot Kaur Ms. Kaur has nothing to disclose.
Abdulrahman Alwaki, MD Dr. Alwaki has nothing to disclose.
Aaron L. Nelson, MD, FAAN Dr. Nelson has nothing to disclose.
Ndubuisi Ahuruonye, MD Dr. Ahuruonye has nothing to disclose.
Erin M. Okazaki, MD Dr. Okazaki has nothing to disclose.
Nitin Agarwal, MBBS Dr. Agarwal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai Inc.
Gregory D. Cascino, MD, FAAN Dr. Cascino has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International League Against Epilepsy . Dr. Cascino has received intellectual property interests from a discovery or technology relating to health care. Dr. Cascino has received publishing royalties from a publication relating to health care. Dr. Cascino has received publishing royalties from a publication relating to health care.
Gary D. Clark, MD The institution of Dr. Clark has received research support from Greewich pharmaceuticals. The institution of Dr. Clark has received research support from Novartis.
Adrian I. Espiritu, MD Dr. Espiritu has nothing to disclose.
Jay D. Desai, MD Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aquestive. The institution of Dr. Desai has received research support from Neurelis, Aquestive, Ovid, Novartis, UCB.
Bryan D. Clements II, DO Mr. Clements has nothing to disclose.
Joseph F. Drazkowski, MD, FAAN Dr. Drazkowski has nothing to disclose.
Prashant Natteru, MBBS Dr. Natteru has nothing to disclose.
Perminder Bhatia, MD Dr. Bhatia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIOHAVEN. Dr. Bhatia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ALLERGAN. Dr. Bhatia has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SK LIFE SCIENCES.
Cigdem I. Akman, MD Dr. Akman has nothing to disclose.
Min Ye Shen, MD Dr. Shen has nothing to disclose.
Eric p. Yeager, MD Mr. Yeager has nothing to disclose.
Nathalie Jette, MD, MSc, FRCPC, FAAN Dr. Jette has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ILAE Epilepsia. The institution of Dr. Jette has received research support from NIH. The institution of Dr. Jette has received research support from AES.
Aasef Shaikh, MD Dr. Shaikh has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda.
Guy M. McKhann, MD No disclosure on file
Eric Jen Eric Jen has received personal compensation for serving as an employee of Neurocrine Biosciences, Inc.
Brian Toh Brian Toh has nothing to disclose.
Irina Podkorytova Irina Podkorytova has nothing to disclose.
Jamie J. Van Gompel, MD Jamie J. Van Gompel, MD has received stock or an ownership interest from Neuroone.
Tara T. Lineweaver, MD Dr. Lineweaver has nothing to disclose.
William C. Leung, MBBS, MRCP, FHKAM Dr. Leung has nothing to disclose.
Dianalee McKnight, PhD Dr. McKnight has nothing to disclose.
Carolyn Tsai, MD Dr. Tsai has nothing to disclose.
Gregory A. Worrell, MD Dr. Worrell has received stock or an ownership interest from NeuroOne Inc.. Dr. Worrell has received stock or an ownership interest from Cadence Neuroscience Inc. The institution of Dr. Worrell has received research support from NIH. The institution of Dr. Worrell has received research support from Medtronic Inc.. The institution of Dr. Worrell has received research support from Neuropace Inc,. The institution of Dr. Worrell has received research support from Epilepsy Foundation of America. Dr. Worrell has received intellectual property interests from a discovery or technology relating to health care. Dr. Worrell has received intellectual property interests from a discovery or technology relating to health care.
Pradeep Chandan, DO Dr. Chandan has nothing to disclose.
Dagmar Amtmann The institution of Dagmar Amtmann has received research support from Zogenix .
Sami M. Aboumatar, MD Dr. Aboumatar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Aboumatar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Aboumatar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion.
Maria Jaramillo, MD Ms. Jaramillo has nothing to disclose.
Sara Dawit, MD Dr. Dawit has nothing to disclose.
Lindsay Kimball Lindsay Kimball has nothing to disclose.
Felippe Borlot, MD Dr. Borlot has nothing to disclose.
Shreya Louis, MD Miss Louis has nothing to disclose.
Marissa Kellogg, MD, MPH Dr. Kellogg has nothing to disclose.
Andreas V. Alexopoulos, MD, MPH Dr. Alexopoulos has nothing to disclose.
Heather Lau, MD Dr. Lau has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prevail Therapeutics. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ASPA Therapeutics. Dr. Lau has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Dr. Lau has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Lau has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chiesi. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orphazyme. Dr. Lau has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biomarin. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Enzyvant. Dr. Lau has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Audentes. Dr. Lau has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Lau has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. The institution of Dr. Lau has received research support from Amicus. The institution of Dr. Lau has received research support from Biomarin. The institution of Dr. Lau has received research support from Genzyme/Sanofi. The institution of Dr. Lau has received research support from Shire/Takeda. The institution of Dr. Lau has received research support from Ultragenyx. The institution of Dr. Lau has received research support from Mallinckrodt. The institution of Dr. Lau has received research support from Orphazyme. The institution of Dr. Lau has received research support from Prevail Therapeutics. The institution of Dr. Lau has received research support from ASPA Therapeutics. The institution of Dr. Lau has received research support from Denail.
Daniel Drane, PhD Dr. Drane has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Medical Directors Solutions, Inc. The institution of Dr. Drane has received research support from NIH/NINDS. The institution of Dr. Drane has received research support from Medtronic, Inc..
Matthew L. Morton, MD Dr. Morton has nothing to disclose.
Stephan Schuele, MD, FAAN Dr. Schuele has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Monteris. Dr. Schuele has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurelis. Dr. Schuele has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Science. Dr. Schuele has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz. Dr. Schuele has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Neurophysiology. Dr. Schuele has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Thomas Needham. Dr. Schuele has received research support from National Institute of Health.
James F. Castellano, MD, PhD The institution of Dr. Castellano has received research support from NIH.
Fernando Cendes, MD, PhD, FAAN Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH.
Ghazala Perven, MD Dr. Perven has nothing to disclose.
E M. Bebin, MD Dr. Bebin has received personal compensation for serving as an employee of Springworks Therapeutics. Dr. Bebin has received personal compensation for serving as an employee of Apertura Gene Therapy. Dr. Bebin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springworks Therapeutics. Dr. Bebin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apertura. The institution of Dr. Bebin has received research support from NINDS. The institution of Dr. Bebin has received research support from FDA Orphan Drug Program.
Jesse W. Mindel, MD Dr. Mindel has nothing to disclose.
Cecilia Peterson An immediate family member of Ms. Peterson has received personal compensation for serving as an employee of 100Plus.
David E. Blum, MD Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.
Peter Van Ess Peter Van Ess has received personal compensation for serving as an employee of Proximagen.
Angela K. Birnbaum, PhD The institution of Dr. Birnbaum has received research support from National Institutes of Health. Dr. Birnbaum has received intellectual property interests from a discovery or technology relating to health care.
Franco E. Appiani, MD Dr. Appiani has nothing to disclose.
William E. Rosenfeld, MD, FAAN The institution of Dr. Rosenfeld has received personal compensation in the range of $500,000-$999,999 for serving as a Consultant for SK Life Science. Dr. Rosenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for SK Life Science.
Jena Grauer No disclosure on file
Leon A. Weinstock, MD Dr. Weinstock has nothing to disclose.
Katherine Liao, PharmD Dr. Liao has nothing to disclose.
Benjamin H. Brinkmann, PhD Dr. Brinkmann has received personal compensation in the range of $0-$499 for serving as a Consultant for Otsuka Pharmaceuticals. Dr. Brinkmann has stock in Cadence Neuroscience. The institution of Dr. Brinkmann has received research support from Epilepsy Foundation of America. The institution of Dr. Brinkmann has received research support from National Institutes of Health. The institution of Dr. Brinkmann has received research support from National Institutes of Health. The institution of Dr. Brinkmann has received research support from UNEEG A/S. The institution of Dr. Brinkmann has received research support from Seer Medical Pty. Dr. Brinkmann has received intellectual property interests from a discovery or technology relating to health care. Dr. Brinkmann has a non-compensated relationship as a Co-Investigator with Medtronic Inc. that is relevant to AAN interests or activities.
Imran I. Ali, MD, FAAN Dr. Ali has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for ABPN.
Prashant Dongre, MD, MBBS Dr. Dongre has received personal compensation for serving as an employee of UCB Inc. Dr. Dongre has stock in UCB Inc.
Antonio Gil-Nagel, MD Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $0-$499 for serving as a Consultant for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EISAI. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoke . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zogenix . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EISAI . Dr. Gil-Nagel has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for GW Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for PTC Therapeutics . Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Gil-Nagel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zogenix . The institution of Dr. Gil-Nagel has received research support from Jazz Pharmaceuticals. The institution of Dr. Gil-Nagel has received research support from PTC Therapeutics. The institution of Dr. Gil-Nagel has received research support from Zogenix. The institution of Dr. Gil-Nagel has received research support from Agencia Estatal Innovacion.
Scott T. Demarest, MD The institution of Dr. Demarest has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ovid. The institution of Dr. Demarest has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biomarin. The institution of Dr. Demarest has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tysha. The institution of Dr. Demarest has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Marinus. The institution of Dr. Demarest has received research support from NIH. The institution of Dr. Demarest has received research support from International Foundation for CDKL5 Research. Dr. Demarest has a non-compensated relationship as a SMAB with SLC6A1 Connect that is relevant to AAN interests or activities. Dr. Demarest has a non-compensated relationship as a SMAB with Ring 14 USA that is relevant to AAN interests or activities. Dr. Demarest has a non-compensated relationship as a SMAB with FamilieSCN2A that is relevant to AAN interests or activities.